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Abstract
Until now, design of the annual influenza vaccine has relied on phylogenetic or whole-
sequence comparisons of the viral coat proteins hemagglutinin and neuraminidase,
with vaccine effectiveness assumed to correlate monotonically to the vaccine-influenza
sequence difference. We use a theory from statistical mechanics to quantify the non-
monotonic immune response that results from antigenic drift in the epitopes of the
hemagglutinin and neuraminidase proteins. The results explain the ineffectiveness
of the 2003–2004 influenza vaccine in the United States and provide an accurate
measure by which to optimize the effectiveness of future annual influenza vaccines.
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1 Introduction
Antigenic variation constitutes one mechanism employed by influenza viruses
to evade the adaptive response of the host immune system. This antigenic drift
of the recognized, epitope regions of the viral surface proteins hemagglutinin
(HA) and neuraminidase (NA) constitutes a major challenge to effective vac-
cine design, where historical experience and phylogenetic analysis of HA and
NA protein sequences from circulating human strains are used to decide the
components of the annual influenza vaccine. Here we introduce a theory to
guide this important public health decision. Application of the theory could
help prevent critical situations such as occurred with 2003–2004 influenza epi-
demic [1], whence the administered A/Panama/2007/99 H3N2 vaccine gave
unexpectedly [2] low protection against the mutant strain A/Fujian/411/2002.
A model from statistical mechanics is used to evaluate the non-linear decrease
of the immune response due to mutations in the viral epitope region sequences.
We propose that this epitope analysis be regularly used as a measure of the
immunological distance between mutant strains in the annual design of the
influenza vaccine.
Influenza A virus infections and posterior complications, such as pneumonia,
are a major cause of human morbidity and mortality. The 2003–2004 influenza
epidemic was mainly due to the proliferation of the new H3N2 subtype strain
A/Fujian/411/2002, an antigenic drift mutant of A/Panama/2007/99. Accord-
ing to the February 2003 WHO report [2], after comparing the whole hemag-
glutinin (HA) sequences of both strains, the CDC council members concluded
that both proteins were similar enough to expect a significant degree of cross
protection, and decided to include the Panama strain in the H3N2 component
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of the vaccine. No information concerning the neuraminidase sequence for the
Fujian strain was used. Recent clinical results, as stated in the 16 January
2004 CDC Morbidity and Mortality Report [1], show the vaccine provided
essentially no protection against infection during the 2003–2004 season.
2 Methods
We have developed a theory of the immune response to an antigenic drift
strain after vaccination based on statistical mechanics, Figure 1 [3]. The model
predicts the affinity constant values
Keq =
[Antigen : Antibody]
[Antigen] [Antibody]
(1)
for a second antigen, after exposure to an original antigen whose epitope region
differs by probability pepitope. The key measure of antigenic drift in the theory
is pepitope, the fractional change between the dominant epitope regions of the
vaccine and the circulating strain, defined by the equation
pepitope =
number of mutations within the epitope
number of amino acids within the epitope
. (2)
This characterization of antigenic drift in our theoretical model emphasizes the
experimental fact that only the epitope regions are significantly involved in
immune recognition, as shown by immunoassays and crystallographic images
[4].
In the theory, it is the percent of the epitope that changes that characterizes
antigenic drift. To provide additional empirical support for the theory, we per-
formed an historical analysis of the influenza seasons between 1991–2000 when
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the H3N2 virus suptype was dominant [5,6,7,8,9,10,11,12,13]. For every sea-
son, hemagglutinin sequences [14] were compared between the vaccine strain
and the predominant circulating strain. A quantitative scale was defined to
measure the seasonal flu severity as follows: low (1), mild (2) and high (3).
The values of seasonal flu severity were correlated with the calculated pepitope
values. In addition, to make clear that the epitope region is primarily respon-
sible for immune recognition, we also correlated the seasonal flu severity with
antigenic drift of the entire hemagglutinin sequence, normalized by the total
number of amino acids in the protein psequence. The results presented in Figure
2 show that seasonal flu severity is correlated with pepitope rather than psequence,
thus favoring the epitope analysis approach. Therefore, it is both logical and
consistent with the observed data to characterize antigenic drift by the number
of mutations within the epitope regions, as we do in the present work.
According to historic clinical experience, and to our model, when the antigenic
drift between the vaccine and circulating strain, characterized by the pepitope
value, is small, exposure to the vaccine antigen leads to a higher affinity con-
stant than without exposure. This result is why immune system memory and
vaccination are generally effective. When the antigenic drift between the vac-
cine and circulating strain is large, the vaccine antigen is uncorrelated with
the circulating strain antigen, and so immune system memory does not play
a role. When the antigenic drift between the vaccine and circulating strain
epitopes is modest (0.23 < pepitope < 0.6), our theory predicts that memory
response may be worse than the naive response (the solid curve lies below
the dashed curve in Figure 1), which means that the immunological memory
from the vaccine exposure actually gives worse protection, i.e., a lower affinity
constant, than would no vaccination whatsoever. This result is the original
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antigenic sin phenomena for influenza: vaccination creates memory sequences
that for some mutation rates of influenza may increase susceptibility to future
exposure [15,16]. Parenthetically, not every infectious disease exhibits original
antigenic sin, with measles one such example. The measles virus does not un-
dergo antigenic drift, and despite approximately eight different subtypes that
have been identified to date [17], the HA and NA genetic variation among
them does not exceed 7% on a nucleotide basis [17], or roughly 2% on an
amino acid basis. Accordingly, within the context of our model, there is no
possibility of original antigenic sin for measles (since pepitope < 0.02, see Figure
1).
Original antigenic sin stems from localization of the immune system response
in antibody sequence space. This localization is a result of the roughness in
sequence space of the evolved antibody affinity constant for antigen. Interest-
ingly, there appears to have been a modest degree of original antigenic sin,
termed negative vaccine effectiveness in the CDC Morbidity and Mortality
report [1], associated with the 2003–2004 influenza vaccine.
Human influenza A viruses are classified in different subtypes according to the
neuraminidase and hemagglutinin proteins. The current influenza A vaccine
includes both the H1N1 and H3N2 subtypes, and the consensus sequence for
the HA and NA proteins corresponding to each subtype requires annual up-
date due to continuous antigenic drift. Variations due to point mutations in
the residues in the epitope regions can considerably reduce the immune re-
sponse, despite biochemical cross activity between strains related by antigenic
drift. The epitope regions of the HA and NA proteins are shown in Figure
3. We propose that antigenic drift mutants be compared not by the whole
sequences of the HA and NA proteins, but more precisely by the sequences
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of the dominant epitopes for the proposed vaccine strain, by calculating the
pepitope parameter of our theory. According to the definition (2), a different
value of pepitope is obtained for each epitope region in both hemagglutinin and
neuraminidase viral proteins. We propose to include in the analysis only the
pepitope values corresponding to the dominant epitopes in both proteins. Since
both hemagglutinin and neuraminidase participate in the immune recognition
process, it is some combination of the immune recognition of these two proteins
that contributes to reducing the seasonal flu severity. We, thus, define an ap-
proximate total response as the binding constant at the average of the pepitope
values for the dominant HA and NA epitopes: pavg =
1
2
(pHAepitope + p
NA
epitope).
3 Results
We compared the epitope sequences of the HA protein to look for mutations
in the A/Fujian/411/2002 strain [14] with respect to the A/Panama/2007/99
strain [18]. The hemagglutinin H3 protein has five epitope regions (A, B, C,
D, E) that have been identified and sequenced [19], among which A and B are
usually dominant [20,21]. There exists experimental and clinical evidence that
epitope regions mutate much faster than other regions in the viral proteins,
presumably due to antibody selective pressure [22,23,24], with the dominant
epitopes mutating most rapidly [25]. Therefore, in the absence of more detailed
information, we take an observed high mutation rate (i.e., a high pepitope value)
in a given epitope to correlate with dominance. Epitope A (residues 122, 124,
126, 130–133, 135, 137, 138, 140, 142–146, 150, 152, 168) presents one point
mutation at residue 131. The calculated value pepitope = 1/19 = 0.053. Epitope
B (residues 128, 129, 155–160, 163, 165, 186–190, 192–194, 196–198) presents
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three point mutations at residues 155, 156, and 186. The calculated value
pepitope = 3/21 = 0.14. Epitope C (residues 44–48, 50, 51, 53, 54, 273, 275, 276,
278–280, 294, 297, 299, 300, 304, 305, 307–312) presents one point mutation at
residue 50. The calculated value pepitope = 1/27 = 0.037. Epitope D (residues
96, 102, 103, 117, 121, 167, 170–177, 179, 182, 201, 203, 207–209, 212–219, 226–
230, 238, 240, 242, 244, 246–248) presents no mutations. Epitope E (residues
57, 59, 62, 63, 67, 75, 78, 80–83, 86–88, 91, 92, 94, 109, 260–262, 265) presents
two point mutations at residues 75 and 83. The calculated value pepitope =
2/22 = 0.09. In absence of further information, which is the typical case for
the annual task of influenza vaccine design, we conclude that likely B epitope
is dominant and E epitope is subdominant for the A/Panama/2007/99 HA
protein, whereas the other epitopes are cryptic. The dominance of epitope B
is in accordance with observed data [26]. Note that by looking at the antigenic
drift within the dominant epitope, rather than the drift of the whole protein
sequence, we obtain a larger and much more accurate estimate of the degree to
which the immune response to A/Fujian/411/2002 and A/Panama/2007/99
will differ.
We also calculated the values for antigenic drift in the NA epitopes be-
tween the A/Fujian/411/2002 [27] and A/Panama/2007/99 [28] strains. The
neuraminidase N2 protein has been completely sequenced and crystallized
[29,30]. Mutational studies with monoclonal antibodies identified three re-
gions (A,B,C) in NA N2 that are important for recognition [4,31], of which
only the surface residues can be within the epitopes. Regions A and B are usu-
ally dominant [31]. Epitope A (residues 383–387, 389–394, 396, 399, 400, 401,
403) presents three point mutations in at residues 385, 399, and 403. The cal-
culated value pepitope = 3/16 = 0.188. Epitope B (residues 197–200, 221, 222)
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presents two point mutations at residues 197 and 217 (although this residue is
not present in the epitope, its mutation will affect the epitope due to physical
proximity). The calculated value pepitope = 2/6 = 0.33. Epitope C (residues
328–332, 334, 336, 338, 339, 341–344, 346, 347, 357–359, 366–370) presents one
point mutation at residue 370. The calculated value pepitope = 1/23 = 0.043.
We conclude that likely epitope B is dominant, and epitope A is subdominant
for the A/Panama/2007/99 NA protein, whereas epitope C is cryptic.
4 Discussion
In Figure 1 are shown the predicted immune responses to the A/Fujian/411/2002
strain for the hemagglutinin (green) and neuraminidase (red) dominant epi-
topes after vaccination to A/Panama/2007/99. The predicted values for hemag-
glutinin lie in the region of moderate immune response, and so consistent with
the WHO data [2] one would expect some degree of cross-strain protection.
However, the predicted immune response to the dominant neuraminidase epi-
tope is in the region of original antigenic sin. In the design of the 2003–2004 in-
fluenza vaccine, neither the cross activity nor the immune response were mea-
sured for the A/Fujian/411/2002 NA protein in response to A/Panama/2007/99
NA vaccination [2]. Upon analysis of actual effectiveness of the 2003–2004 vac-
cine, there does appear to have been a modest degree of original antigenic sin,
or negative vaccine effectiveness [1].
Summarizing our findings, it would appear that for the hemagglutinin protein
of A/Panama/2007/99, epitope B is dominant, and vaccination gives modest
protection to the A/Fujian/411/2002 strain. For the neuraminidase protein
of A/Panama/2007/99, it would appear that epitope B is also dominant, and
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vaccination may increase the susceptibility to the A/Fujian/411/2002 strain.
Taken in aggregate, these results, Figure 1, suggest that the 2003–2004 flu vac-
cine would have essentially no effect against the circulating A/Fujian/411/2002
strain, in agreement with clinical findings [1] and in disagreement with early
expectations [2].
In conclusion, we suggest that strains related by antigenic drift be compared
by measuring differences in the epitope regions of the hemagglutinin and neu-
raminidase proteins and not by differences in the whole sequence or phylogeny
as is presently done. This particular point is supported by the correlations of
seasonal flu severity with epitope antigenic drift shown in Figure 2. Thus, there
is a need for a detailed characterization of the epitope regions in the differ-
ent influenza strains. In particular, a precise determination of which epitopes
are dominant in the proposed vaccine strain and an experimental measure of
pepitope and of cross activity between the proposed vaccine strain and the cir-
culating strains would be highly productive. In absence of this determination,
we suggest to estimate the dominant epitope as that which shows the most
antigenic drift [22,23,24,25], as we do in the present work. From either epitope
sequence drift or cross activity, Figure 1 can be used to estimate the degree
of the immune response, which is a non-linear and non-monotonic function of
the measured data. We believe that this quantitative epitope analysis should
be incorporated as part of the regular protocol for construction of the annual
influenza vaccine.
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Figures
Fig. 1. The evolved affinity constant to a second antigen after exposure to an original
antigen whose epitope region differs by probability pepitope (solid line). The dashed
line represents the affinity constant without previous exposure. In green are shown
the responses at the values of the differences between the A/Panama/2007/99 (vac-
cine) and A/Fujian/411/2002 (circulating) strains for the B and E hemagglutinin
epitopes. In red are shown the responses at the values of the difference between
the A/Panama/2007/99 (vaccine) and A/Fujian/411/2002 (circulating) strains for
the A and B neuraminidase epitopes. Dominant epitopes are shown in bold. The
clinical outcome is an average of the response to the HA and NA proteins, and in
purple is shown the immune response at the average difference for the dominant
HA and NA epitopes (see text). The effectiveness of the 2003–2004 flu vaccine was
marginal at best. In inset is shown the cross affinity of the memory sequences for
the mutated antigen, often measured biochemically and distinct from the evolved
immune response. As if often found, the cross activity decreases exponentially with
antigenic drift [32].
Fig. 2. a) Correlation between influenza seasonal severity (see text) and hemagglu-
tinin antigenic drift, calculated by epitope analysis. Least-squares regression anal-
ysis yields the linear fit y = 1.5425 + 5.9162 pepitope , with a correlation coefficient
R = 0.54432. b) Correlation between influenza seasonal severity (see text) and
hemagglutinin antigenic drift, calculated by whole sequence analysis. Least-squares
regression analysis yields the linear fit y = 2.0041 + 11.684 psequence , with a correla-
tion coefficient R = 0.2183.
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Fig. 3. a) Shown are the dominant B (top) and subdominant E (middle) epitope
of the hemagglutinin protein in space-filling format [19]. b) Shown are the domi-
nant B (right) and subdominant A (left) epitope of the neuraminidase protein in
space-filling format [30]. The rest of the proteins are shown in ribbon format.
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